SAMANTHA HERNANDEZ: Open Payments
NPI 1457018368 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$772 in 35 payments from 10 companies in 2025. Trend: 2023 $289 · 2024 $453 · 2025 $772
Food & beverage: $772
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $273 |
| Axsome Therapeutics, Inc. | 3 | $166 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $84 |
| Teva Pharmaceuticals USA, Inc. | 3 | $73 |
| Neurocrine BioSciences, Inc. | 2 | $45 |
| Alkermes, Inc. | 2 | $43 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: VRAYLAR, Auvelity, CAPLYTA, AUSTEDO XR, INGREZZA, ARISTADA, SPRAVATO, UZEDY.
Industry payments across TX — which companies pay providers there.
